Outset Medical, Inc. develops and commercializes dialysis technology centered on the Tablo Hemodialysis System, an FDA-cleared platform used across hospital and home care settings. Company news commonly covers Tablo adoption, consumables and service revenue, product gross margin, cash use, and financial guidance tied to the company’s medical technology business.
Recurring updates also include FDA matters for the Tablo platform, including 510(k) clearance for a next-generation system with cybersecurity, reliability, and connectivity enhancements. Governance and compensation announcements include board changes, executive appointments, and inducement equity grants under Nasdaq rules.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Outset Medical, Inc. (NASDAQ: OM), a pioneering medical technology firm, announced its participation in two upcoming investor conferences. The Bank of America Securities 2023 Health Care Conference is scheduled for May 9, 2023, at 1:40 PM PT, while the RBC Capital Markets Global Healthcare Conference will take place on May 17, 2023, at 5:00 AM PT. Live and archived webcasts of these events will be accessible via the Outset Investors' website.
Outset's flagship product, the Tablo Hemodialysis System, aims to streamline dialysis, making it more accessible and efficient for patients and providers. This innovative system integrates water purification and on-demand dialysate production, positioning it as a versatile solution for dialysis care.